

Fund Performance

Returns ¹	Month	Quarter	FYTD	6 Months	1 Year	3 Years p.a.	Since Inception p.a. (20-Aug-2019)
Fund Net Return	0.61%	0.62%	3.87%	4.20%	14.11%	-	11.63%
Benchmark Return	0.01%	0.03%	0.04%	0.07%	0.37%	-	0.45%
Active Return (After fees)	0.60%	0.59%	3.83%	4.14%	13.75%	-	11.18%

Fund Benefits

About the Fund

- CC Sage Capital Absolute Return Fund (the Fund) is a market neutral or absolute return strategy, giving investors exposure to Sage Capital's stock selection skills while eliminating exposure to the underlying equity market.
- The Fund provides a source of uncorrelated returns to equity markets - where short positions and long positions offset each other.

Fund Facts

Portfolio Managers	Sean Fenton, Kelli Meagher, James Delaney, Peter Moore
Structure	Australian unit trust
Investment Style	A market neutral long/short strategy
Net Asset Value	\$25.7 million ²
Inception Date	20 Aug 2019
Benchmark	RBA Cash Rate
Management Fee	1.29% p.a. ³
Administration Fee	0.10% p.a. ³
Performance Fee	20.5% p.a. ⁴
Distributions	Semi-annually at 31 December and 30 June
Minimum Suggested Investment Period	At least 5 years
Exit Price	\$1.1376
Long Exposure	83%
Short Exposure	-83%
Gross Exposure	166%
Net Exposure	1%

Platform Availability

BT Panorama	BT Wrap
Colonial First Wrap	HUB 24 IDPS
Mason Stevens	Netwealth
Praemium IDPS	

¹ Performance is for the CC Sage Capital Absolute Return Fund ('the Fund') - Class A, and is based on month end unit prices in Australian Dollars. Net return is calculated after Fund management fees and operating costs. Individual Investor level taxes are not taken into account when calculating net returns. This is historical performance data. It should be noted the value of an investment can rise and fall and past performance is not indicative of future performance. ² Net Asset Value refers to the CC Sage Capital Absolute Return Fund ARSN 634 149 287 and is calculated as Fund assets less Fund liabilities. ³ All figures disclosed include the net effect of GST and RITC. ⁴ Performance Fee of 20.5% based on outperformance over the Fund Benchmark, net of the Management Fee and includes the net effect of GST and RITC.

Top 5 Holdings

Stock Name	Sector
ResMed Inc	Health Care
Appen Ltd	Information Technology
QBE Insurance Group Ltd	Financials
Ansell Ltd	Health Care
BlueScope Steel Ltd	Materials

Sector Allocation Weight

Sector Name	Fund
Communication Services	-4.56%
Consumer Discretionary	3.87%
Consumer Staples	0.57%
Energy	-1.63%
Financials	1.58%
Health Care	7.74%
Industrials	-4.71%
Information Technology	0.66%
Materials	0.66%
Real Estate	-0.31%
Utilities	-3.20%

Fund Disclosures

Key service provider changes	Nil
Key individual changes	Nil
Risk profile or investment strategy material changes	Nil

Further Information

Phone:	1800 940 599
Email:	distribution@channelcapital.com.au
Web:	www.channelcapital.com.au

Performance Review

The CC Sage Capital Absolute Return Fund returned 0.61% in October, resulting in an outperformance of 0.60% relative to the RBA Cash Rate of 0.01%.

Key stock contributors for the month were long positions in Coca Cola Amatil (CCL +31%) which received a takeover offer from Coca Cola European Partners, ResMed (RMD +17%) which delivered a very strong third quarter result significantly above market expectations, driven by increased sales of ventilators and a strong recovery in demand for its core flow generator and mask products and BlueScope Steel (BSL +15%) which issued a strong earnings outlook on the back of improving steel spreads and strength in demand for both renovations and detached housing. Our short position in AGL (-8%) also aided performance, giving a downbeat outlook for wholesale electricity prices and increased gas supply costs. Key detractors for the month were long positions in Coronado Global Resources (CRN -22%), which fell on downside risk to coal prices should China continue to restrict Australian coal imports and Corporate Travel (CTD -15%), which sold off on fears of a second wave of COVID-19 in the Northern Hemisphere, and a short position in Afterpay (APT +21%) which rallied after giving a strong 1Q21 trading update.

Market Review

In October, the S&P/ASX 200 Accumulation Index rose by 1.9%, outperforming major markets in the Northern Hemisphere. While Australia looks to have COVID-19 largely under control, October saw cases in Europe and the UK continue to rise rapidly resulting in full or partial mobility restrictions in France, Germany, Italy and Spain. The US also continued to see a rise in cases with President Trump himself contracting the virus. Fears of the economic impact of a second wave and US election uncertainty weighed on global markets with the S&P 500 Index down 2.8% and MSCI World ex-Australia down 3.2%.

In Australia, consumer confidence and business conditions continued to improve in October with the Federal Government delivering a budget which was well received, with larger than expected fiscal stimulus including acceleration in tax cuts, incentives for businesses to hire and invest as well as an acceleration in infrastructure spending and housing incentives. Best performing sectors were Information Technology (+9%) followed by Financials (+6.3%), Consumer Staples (+4.8%) and Consumer Discretionary (1.5%). Industrials (-3.9%) was the worst performing sector followed by Utilities (-1.5%) and Energy (-0.8%).

Market Outlook

Market direction in the short term is likely to be heavily influenced by the outcome of the US election. As voting currently stands, Joe Biden will be the next President although the blue sweep of both houses hasn't eventuated. The Republicans will control the senate which reduces the likelihood of big fiscal spending and expected increases in corporate taxes may be traded off to achieve some stimulus. Markets like this outcome, because the lower growth outlook boosts the chances of further QE and lower bond yields boosting valuations. Bad news is good news, but the effect may be short lived.

We see a markedly increased chance of having a successful COVID-19 vaccine candidate by the end of 2020. The structure of the phase 3 trial designs of many candidates have them doing an interim analysis for efficacy when a certain number of symptomatic coronavirus cases are hit. The increasing infection rates in the US and other parts of the world means that the longer it takes to reach these thresholds, the higher the likely efficacy of the vaccine. The fact that we haven't had any trials report interim data before the US election, as was speculated earlier, increases the likelihood that when they do report they will show strong efficacy. A promising vaccine candidate can possibly take the place of fiscal stimulus. A quicker end to social distancing will help lift employment and spending and should drive a steepening in the yield curve and a rotation to value. There are a range of stocks that will do well from this normalisation, with those linked to travel and leisure expenditure receiving the biggest lift. Conversely, the boom in online retailing and expenditure on homewares may flatten out, although the Sage Capital investment team expect to see a strong Christmas trading period for many retailers.

Another interesting dynamic shaping our market is the increasing trade tension between China and Australia. China have either halted imports or are examining tariffs on a range of goods from coal and wine to barley and lobsters. Escalation here could have implications for Australia's post-COVID-19 recovery if it extends to Chinese students and tourists. Sage Capital sees risks around stocks exposed to Chinese exports and the daigou channel.

With many significant global influences at play regarding US election outcome impacts, trajectory of COVID-19 cases and timing of a successful vaccine, Sage Capital continue to manage risk tightly to avoid sector and style bias and minimise systematic risk in the portfolio and ensure returns are achieved through stock selection.

The information contained in this report is provided by the Investment Manager, Sage Capital Pty Ltd ACN 632 839 877 AR No. 001276472 ('Sage Capital'). Channel Investment Management Limited ACN 163 234 240 AFSL 439007 ('CIML') is the Responsible Entity and issuer of units in the CC Sage Capital Absolute Return Fund ARSN 634 149 287 ('the Fund'). Neither CIML nor Sage Capital, their officers, or employees make any representations or warranties, express or implied as to the accuracy, reliability or completeness of the information contained in this report and nothing contained in this report is or shall be relied upon as a promise or representation, whether as to the past or the future. Past performance is not a reliable indication of future performance. This information is given in summary form and does not purport to be complete. Information in this report, should not be considered advice or a recommendation to investors or potential investors in relation to holding, purchasing or selling units in the Fund and does not take into account your particular investment objectives, financial situation or needs. Before acting on any information you should consider the appropriateness of the information having regard to these matters, any relevant offer document and in particular, you should seek independent financial advice. Readers are cautioned not to place undue reliance on forward looking statements. Neither CIML nor Sage Capital have any obligation to publicly release the result of any revisions to these forward looking statements to reflect events or circumstances after the date of this report. For further information and before investing, please read the Product Disclosure Statement available from www.sagecap.com.au and www.channelcapital.com.au.